[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SV1997000049A - Conjugados de interferones ref. 12614 sv - Google Patents

Conjugados de interferones ref. 12614 sv

Info

Publication number
SV1997000049A
SV1997000049A SV1997000049A SV1997000049A SV1997000049A SV 1997000049 A SV1997000049 A SV 1997000049A SV 1997000049 A SV1997000049 A SV 1997000049A SV 1997000049 A SV1997000049 A SV 1997000049A SV 1997000049 A SV1997000049 A SV 1997000049A
Authority
SV
El Salvador
Prior art keywords
conjugates
interferones
ref
illnesses
effects
Prior art date
Application number
SV1997000049A
Other languages
English (en)
Inventor
Pascal Sebastian Bailon
Palleroni Alicia Vallejo
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV1997000049(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SV1997000049A publication Critical patent/SV1997000049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A CONJUGADOS DE POLIETILENGLICOL, SOLUBLES EN AGUA, FISIOLÓGICAMENTE ACTIVOS, CON INTERFERÓN, Y A NUEVOS COMPUESTOS DE POLIETILENGLICOL, QUE PUEDEN EMPLEARSE EN AL PREPARACIÓN DE LOS CONJUGADOS, INDICADOS PARA TRATAR ENFERMEDADES TALES COMO EOPLASMATICAS O ENFERMEDADES INFECCIOSAS
SV1997000049A 1996-05-31 1997-05-30 Conjugados de interferones ref. 12614 sv SV1997000049A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31

Publications (1)

Publication Number Publication Date
SV1997000049A true SV1997000049A (es) 1998-07-09

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1997000049A SV1997000049A (es) 1996-05-31 1997-05-30 Conjugados de interferones ref. 12614 sv

Country Status (48)

Country Link
US (1) US7201897B2 (es)
EP (1) EP0809996B1 (es)
JP (1) JP2980569B2 (es)
KR (1) KR100254097B1 (es)
CN (1) CN1088721C (es)
AR (1) AR008378A1 (es)
AT (1) ATE235920T1 (es)
AU (1) AU725195B2 (es)
BG (1) BG62273B1 (es)
BR (1) BR9703421A (es)
CA (1) CA2203480C (es)
CO (1) CO4950528A1 (es)
CY (2) CY2433B1 (es)
CZ (1) CZ292775B6 (es)
DE (3) DE69720320T2 (es)
DK (1) DK0809996T3 (es)
EG (1) EG24292A (es)
ES (1) ES2110386T3 (es)
GR (1) GR970300063T1 (es)
HK (1) HK1005225A1 (es)
HR (1) HRP970298B1 (es)
HU (1) HU227992B1 (es)
IL (1) IL120902A (es)
IS (1) IS1988B (es)
LU (1) LU91029I2 (es)
MA (1) MA24193A1 (es)
MY (1) MY117909A (es)
NL (1) NL300127I2 (es)
NO (1) NO322964B1 (es)
NZ (1) NZ314903A (es)
OA (1) OA10488A (es)
PA (1) PA8431001A1 (es)
PL (1) PL186949B1 (es)
PT (1) PT809996E (es)
RS (1) RS49533B (es)
RU (1) RU2180595C2 (es)
SA (1) SA97180030B1 (es)
SG (1) SG55314A1 (es)
SI (1) SI0809996T1 (es)
SK (1) SK284458B6 (es)
SV (1) SV1997000049A (es)
TJ (1) TJ328B (es)
TN (1) TNSN97091A1 (es)
TR (1) TR199700358A3 (es)
TW (1) TW517067B (es)
UA (1) UA56989C2 (es)
UY (1) UY24572A1 (es)
ZA (1) ZA974583B (es)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
PL196533B1 (pl) * 1998-04-28 2008-01-31 Applied Research Systems Sposób stopniowego przyłączania ugrupowań poli (glikolu etylenowego) (PEG) szeregowo do polipeptydu
ATE216591T1 (de) 1998-05-15 2002-05-15 Schering Corp Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
ATE307597T1 (de) * 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
DK1043026T3 (da) 1999-04-08 2005-07-04 Schering Corp Melanombehandling
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
NZ514417A (en) * 1999-04-08 2003-10-31 Schering Corp Use of pegylated interferon alpha in chronic myeloid leukemia (CML) therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
AR027509A1 (es) 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
AU2001232951A1 (en) * 2000-01-24 2001-07-31 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
WO2002002627A2 (en) 2000-06-30 2002-01-10 Zymogenetics, Inc. Interferon-like protein zcyto21
US7291713B2 (en) 2001-01-30 2007-11-06 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
KR100888371B1 (ko) * 2002-01-17 2009-03-13 동아제약주식회사 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
CA2492775C (en) 2002-07-24 2011-06-21 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
ES2214166T1 (es) * 2002-09-11 2004-09-16 Fresenius Kabi Deutschland Gmbh Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada.
BR0314227A (pt) * 2002-09-11 2005-10-25 Fresenius Kabi De Gmbh Derivados de amido de hidroxialquila
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
DE60323756D1 (de) 2002-10-08 2008-11-06 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
MXPA05005263A (es) * 2002-11-18 2005-07-25 Maxygen Inc Polipeptidos y conjugados de interferon alfa.
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ATE481420T1 (de) 2003-10-10 2010-10-15 Novo Nordisk As Il-21-derivate
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
EP1725589A1 (en) 2004-03-11 2006-11-29 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
CA2566247A1 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
BRPI0513332A (pt) 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
KR20080019619A (ko) 2005-05-18 2008-03-04 맥시겐, 인크. 개량된 인터페론-알파 폴리펩티드
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP1901777A2 (en) * 2005-06-20 2008-03-26 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon-alpha analogs and interferon tau
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
AU2006315347A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
JPWO2007132882A1 (ja) 2006-05-16 2009-09-24 財団法人 東京都医学研究機構 Ｈｃｖ感染症を治療または予防するための医薬組成物
WO2007135182A2 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor ix analogues having prolonged in vivo half life
DK2061878T3 (da) 2006-09-08 2014-04-07 Ambrx Inc Hybridsuppressor-trna for hvirveldyrceller
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
CN1966547B (zh) * 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
DE602007005165D1 (de) * 2006-11-07 2010-04-15 Dsm Ip Assets Bv Carbamat, thiocarbamat oder carbamid mit einer biomolekularen gruppierung
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja) 2007-02-28 2014-06-11 日油株式会社 多分岐鎖ポリオキシアルキレン誘導体
MX2009010531A (es) 2007-03-30 2009-11-26 Ambrx Inc Polipeptidos de fgf-21 modificados y usos de los mismos.
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ATE548382T1 (de) 2007-09-04 2012-03-15 Biosteed Gene Expression Tech Co Ltd Polyethylenglykolmodifiziertes interferon alpha 2b und herstellungsverfahren und anwendungen davon
PT2196475E (pt) 2007-09-04 2012-09-07 Biosteed Gene Expression Tech Co Ltd Interferão alfa-2a modificado por polietilenoglicol, seu processo de síntese e aplicação
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CA2711375C (en) * 2008-01-18 2019-04-16 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
CN101980725B (zh) * 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
BRPI0822530B1 (pt) 2008-04-03 2022-03-22 Biosteed Gene Expression Tech. Co., Ltd Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição
LT2279007T (lt) 2008-04-29 2016-10-10 Ascendis Pharma Growth Disorders Division A/S Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
CA2729943A1 (en) 2008-07-08 2010-01-14 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
PL3225248T3 (pl) 2008-07-23 2023-11-27 Ambrx, Inc. Zmodyfikowane polipeptydy bydlęcego G-CSF i ich zastosowania
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
ES2631915T3 (es) 2008-09-26 2017-09-06 Ambrx, Inc. Polipéptidos modificados de eritropoyetina animal y sus usos
IT1399351B1 (it) 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
BR112012033022A2 (pt) 2010-06-24 2016-12-20 Genosciense Pharma Sas tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
JP2013541937A (ja) 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PT3572091T (pt) 2010-08-17 2024-03-01 Ambrx Inc Polipéptidos de relaxina modificados e as suas utilizações
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
JP2014522641A (ja) 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
US20140377218A1 (en) 2011-08-03 2014-12-25 Cytheris Hcv immunotherapy
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP3584255B1 (en) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EA022617B1 (ru) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
EA023323B1 (ru) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
ES2966888T3 (es) * 2014-11-06 2024-04-24 Pharmaessentia Corp Régimen de dosificación para el interferón pegilado
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric human growth hormone drug matrices
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
BR112018009009A8 (pt) 2015-11-03 2019-02-26 Hoffmann La Roche terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
US12049485B2 (en) 2018-09-11 2024-07-30 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
CN115243726A (zh) 2020-03-11 2022-10-25 北京泰德制药股份有限公司 白介素-2多肽偶联物及其使用方法
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
WO2022140783A1 (en) * 2020-12-23 2022-06-30 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
ATE136315T1 (de) * 1989-05-27 1996-04-15 Sumitomo Pharma Verfahren für die herstellung von polyethylenglykolderivate und modifizierte proteine.
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
ATE214940T1 (de) * 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
DK0726778T3 (da) * 1994-02-08 2001-09-24 Amgen Inc Oral administration af kemisk modificerede proteiner
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
TJ97000465A (en) 1998-12-25
PL186949B1 (pl) 2004-04-30
AU725195B2 (en) 2000-10-05
ES2110386T1 (es) 1998-02-16
NL300127I1 (es) 2003-07-01
YU17597A (sh) 1999-07-28
JP2980569B2 (ja) 1999-11-22
CZ292775B6 (cs) 2003-12-17
OA10488A (fr) 2002-04-11
PA8431001A1 (es) 2000-05-24
DE809996T1 (de) 1998-04-09
CY2433B1 (en) 2004-11-12
CY2005006I1 (el) 2009-11-04
HRP970298B1 (en) 2003-08-31
SK67397A3 (en) 1997-12-10
NO972480D0 (no) 1997-05-30
BR9703421A (pt) 1998-09-15
AU2372397A (en) 1997-12-04
IS4491A (is) 1997-12-01
PT809996E (pt) 2003-06-30
MY117909A (en) 2004-08-30
EP0809996A2 (en) 1997-12-03
AR008378A1 (es) 2000-01-19
CN1088721C (zh) 2002-08-07
TW517067B (en) 2003-01-11
MX9704012A (es) 1997-11-29
ES2110386T3 (es) 2003-10-01
PL320251A1 (en) 1997-12-08
DE10399018I1 (de) 2003-10-23
CA2203480A1 (en) 1997-11-30
RS49533B (sr) 2006-12-15
HU227992B1 (en) 2012-08-28
TNSN97091A1 (fr) 2005-03-15
HUP9700959A3 (en) 1998-03-30
HUP9700959A2 (hu) 1998-03-02
DE69720320D1 (de) 2003-05-08
TR199700358A2 (xx) 1997-12-21
NL300127I2 (nl) 2003-09-01
SK284458B6 (sk) 2005-04-01
LU91029I2 (fr) 2004-01-23
EG24292A (en) 2009-01-08
CA2203480C (en) 2009-06-30
SA97180030B1 (ar) 2005-11-12
UY24572A1 (es) 2000-12-29
NO972480L (no) 1997-12-01
EP0809996B1 (en) 2003-04-02
ZA974583B (en) 1998-11-17
HU9700959D0 (en) 1997-07-28
TJ328B (en) 2001-12-24
IL120902A0 (en) 1997-09-30
HK1005225A1 (en) 1998-12-31
IS1988B (is) 2005-02-15
US20040030101A1 (en) 2004-02-12
RU2180595C2 (ru) 2002-03-20
NO322964B1 (no) 2006-12-18
NZ314903A (en) 1998-10-28
GR970300063T1 (en) 1998-01-30
TR199700358A3 (tr) 1997-12-21
US7201897B2 (en) 2007-04-10
DK0809996T3 (da) 2003-07-21
SI0809996T1 (en) 2003-08-31
EP0809996A3 (en) 1999-04-14
HRP970298A2 (en) 1998-04-30
MA24193A1 (fr) 1997-12-31
CO4950528A1 (es) 2000-09-01
KR970074791A (ko) 1997-12-10
UA56989C2 (uk) 2003-06-16
BG62273B1 (bg) 1999-07-30
JPH1067800A (ja) 1998-03-10
ATE235920T1 (de) 2003-04-15
CZ167997A3 (en) 1997-12-17
DE69720320T2 (de) 2004-06-03
CY2005006I2 (el) 2009-11-04
KR100254097B1 (ko) 2000-05-01
CN1167777A (zh) 1997-12-17
SG55314A1 (en) 1998-12-21
BG101540A (en) 1998-02-27
IL120902A (en) 2004-06-20

Similar Documents

Publication Publication Date Title
SV1997000049A (es) Conjugados de interferones ref. 12614 sv
LV10907A (lv) Interferona polietilenglikola atvasinajums
PT758248E (pt) Formulacoes para o factor ix
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
FR2674754B1 (fr) Composition medicamenteuse micronisee.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
AR241022A1 (es) "fosfatidos de eteres de glicerina y procedimiento para su preparacion"
DK0402637T3 (da) Stabilt frysetørret polyhæmatoporphyrinether/esterpræparat
SV1998000040A (es) Composiciones farmaceuticas ref. pu3210/sv
MX9100357A (es) Composiciones farmaceuticas estabilizadas y procedimiento para su preparacion
AR240400A1 (es) Procedimiento para obtener nuevas composiciones sinergicas para uso veterinario.
DK13087A (da) Gensekvens til fremstilling af human serumalbumin i bacillus
DE68908414D1 (de) Pharmazeutische zusammensetzungen fuer die reizung eines immunostimulierenden effektes.
TR199900013T2 (xx) Yeni bile�ikler.
AR009322A1 (es) Nuevas aril-piridazinas
IT1150194B (it) Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
SV1990000045A (es) Preparacion de cicloalcano [b] dehidroindol e-inosulfonamidas sustituidas, ref. le a 27 157-sv.
IT8822438A0 (it) Procedimento per la preparazione di ceftriaxone e i suoi sali farmaceuticamente accettabili.
IT8922279A0 (it) Formulazioni farmaceutiche per uso topico
GT199200058A (es) Conjugados de proteinas con polietilenglicol
ECSP982715A (es) Derivados de pleuromutilina y su uso en terapia antimicrobiana
UA2094S (uk) Етикетка медичного препарату "аспаркам"
UA1957S (uk) Етикетка медичного препарату "аспаркам"

Legal Events

Date Code Title Description
FG Grant
FD Lapse